Global Pulmonary Drugs Market Size (2024 - 2029)

The pulmonary drugs market is experiencing growth driven by an increasing prevalence of respiratory diseases and a growing geriatric population. The COVID-19 pandemic has positively influenced the market size due to heightened awareness and demand for treatments related to asthma and Chronic Obstructive Pulmonary Disease (COPD), as these conditions are associated with higher risks from the virus. Environmental factors, such as pollution and secondhand smoke, contribute to the rising incidence of respiratory disorders, further expanding the market. However, the market's expansion is challenged by stringent government regulations and potential side effects of drugs.

Market Size of Global Pulmonary Drugs Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Pulmonary Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.40 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Pulmonary Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Pulmonary Drugs Market Analysis

The pulmonary drugs market is expected to register a CAGR of 5.4% over the forecast period (2022-2027).

The COVID-19 pandemic and lockdowns in various countries across the world have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, owing to the strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a positive impact on the global pulmonary drugs market, due to patients with asthma and Chronic Obstructive Pulmonary Disease (COPD) being considered at increased risk of death from Covid-19. For instance, in August 2021, according to data published by National Center for Biotechnology Information, Asthma statistics worldwide for 2020 showed that more than 339 million individuals have asthma and that around four million children develop asthma each year on a global level. Thus, increasing cases of COVID-19 are rising the cases of respiratory disorders which generates the need for pulmonary drugs.

Additionally, various clinical research studies based on SARS-CoV-2 showcased that the virus is capable of changing pulmonary hemodynamics through the mechanisms of venous thromboembolism, endothelial dysfunction, thrombotic microangiopathy, and vascular leak. For instance, In January 2021, the National Center for Biotechnology Information (NCBI) published a study that states that those patients who died of COVID-19, exhibited thickened pulmonary vascular walls. This shows that in the future, SARS-CoV-2 can trigger the high susceptibility of infected individuals to developing pulmonary arterial hypertension. Thus, COVID-19 has a significant impact on market growth.

Certain factors that are driving the market growth include the rising prevalence of pulmonary diseases and the growing geriatric population. Pulmonary diseases affect the airways and other parts of the lungs for a long duration of the period. Respiratory symptoms are among the major causes of consultation with doctors and physicians in primary health care centers. Some of the major preventable chronic respiratory disorders are asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, sleep apnea, and tuberculosis (principally, multi-drug resistant tuberculosis). As per the Asthma and allergy foundation of America published in March 2021, Roughly 1 in 13 Americans have asthma, which is about 25 million people. Asthma is one of the largest contributors to this figure, affecting children, adults, and elderly people. The same source stated that about 5 million American children have asthma. There is a high prevalence of severe asthma in the Middle East & Africa and the Latin America region as compared to the mid-range of prevalence in North America, Europe, and Asia-Pacific countries.

Another reason for the increased prevalence of respiratory diseases is the excessive environmental pollution in metropolitan cities and industrial lands. In addition, secondhand smoke exposure also leads to serious respiratory diseases. Stringent government regulations for product approval and side effects associated with drugs are hampering the growth of the market.

Pulmonary Drugs Industry Segmentation

As per the scope of the report, pulmonary diseases refer to the types of diseases that affect the lungs and other parts of the respiratory system. Pulmonary diseases may be caused by infection, by smoking tobacco, or by breathing in secondhand tobacco smoke, radon, asbestos, or other forms of air pollution. Pulmonary drugs are the branch of medicine that deals with the causes, diagnosis, prevention, and treatment of such pulmonary diseases. The Pulmonary Drugs Market is segmented by Drug Class (Beta-2 Agonists, Anticholinergic Agents, Oral and Inhaled Corticosteroids, Anti-leukotrienes, Antihistamines, Monoclonal Antibodies, Combination Drugs, and others), Indication (Asthma, COPD (Chronic Obstructive Pulmonary Disease), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Beta-2 Agonists
Anti-cholinergic Agents
Oral and Inhaled Corticosteroids
Anti-leukotrienes
Antihistamines
Monoclonal Antibodies
Combination Drugs
Others
By Indication
Asthma
COPD (Chronic Obstructive Pulmonary Disease)
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Pulmonary Drugs Market Size Summary

The pulmonary drugs market is poised for significant growth, driven by the increasing prevalence of respiratory diseases and a rising geriatric population. The market has been positively influenced by the COVID-19 pandemic, which highlighted the vulnerability of individuals with asthma and Chronic Obstructive Pulmonary Disease (COPD), thereby boosting the demand for pulmonary medications. The pandemic also underscored the potential long-term pulmonary complications associated with SARS-CoV-2, such as pulmonary arterial hypertension, further propelling market expansion. Environmental factors, including pollution and secondhand smoke, have contributed to the rising incidence of respiratory disorders, necessitating the use of pulmonary drugs. Despite challenges such as stringent regulatory requirements and drug side effects, the market is expected to benefit from technological advancements and the development of novel targeted therapies.

The competitive landscape of the global pulmonary drugs market is characterized by the presence of major pharmaceutical players like AstraZeneca, Boehringer Ingelheim, and Merck & Co., among others. These companies are actively engaged in strategic initiatives such as product launches, collaborations, and clinical trials to enhance their market share. The market's growth is further supported by increased health expenditure, government and non-government initiatives, and advanced healthcare infrastructure. Research and development activities aimed at discovering new treatments for respiratory diseases are also contributing to market dynamics. As the market continues to evolve, the focus on innovative therapies and the management of chronic respiratory conditions is expected to drive sustained growth over the forecast period.

Explore More

Global Pulmonary Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Pulmonary Diseases

      2. 1.2.2 Increasing Burden of Geriatric Population

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Government Regulations for Product Approval

      2. 1.3.2 Side Effects Associated With Drugs

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Drug Class

      1. 2.1.1 Beta-2 Agonists

      2. 2.1.2 Anti-cholinergic Agents

      3. 2.1.3 Oral and Inhaled Corticosteroids

      4. 2.1.4 Anti-leukotrienes

      5. 2.1.5 Antihistamines

      6. 2.1.6 Monoclonal Antibodies

      7. 2.1.7 Combination Drugs

      8. 2.1.8 Others

    2. 2.2 By Indication

      1. 2.2.1 Asthma

      2. 2.2.2 COPD (Chronic Obstructive Pulmonary Disease)

      3. 2.2.3 Allergic Rhinitis

      4. 2.2.4 Pulmonary Arterial Hypertension

      5. 2.2.5 Cystic Fibrosis

      6. 2.2.6 Others

    3. 2.3 By Distribution Channel

      1. 2.3.1 Hospital Pharmacies

      2. 2.3.2 Retail Pharmacies

      3. 2.3.3 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Pulmonary Drugs Market Size FAQs

The Global Pulmonary Drugs Market is projected to register a CAGR of 5.40% during the forecast period (2024-2029)

Boehringer Ingelheim, Merck & Co., AstraZeneca PLC, GlaxoSmithKline PLC and Grifols, S.A. are the major companies operating in the Global Pulmonary Drugs Market.

Pulmonary Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)